After holding the state’s second-largest biotech IPO earlier this year, a company aiming to make drugs that rebalance the billions of bacteria in the gut will soon be the largest tenant at a new development by BioMed Realty Trust.
The development company, which specializes in developing lab space for life science firms, said that Seres Therapeutics (Nasdaq: MCBM) is leasing 83,000 square feet at 200 Sidney St. The company will be the final tenant at the building, as well as its largest, joining AbbVie, CRISPR Therapeutics, RaNA Therapeutics and Synlogic.
